SCHEMBL17312604

SCHEMBL17312604

CC(C)(C)N(C(=O)O)C1CCc2ccc(O)cc2NC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.35
OPRD1 P41143 3/20 0.35
OPRK1 P41145 3/20 0.35
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
ACHE P22303 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
CRBN Q96SW2 2/20 0.33
DDB1 Q16531 1/20 0.33
AR P10275 2/20 0.33
ESR2 Q92731 2/20 0.33
AKR1B10 O60218 1/20 0.33
LMNA P02545 1/20 0.33
ESR1 P03372 1/20 0.33
SHBG P04278 1/20 0.33
CYP1A2 P05177 1/20 0.33
PGR P06401 1/20 0.33
SERPINA6 P08185 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17312602 1.00 OPRM1 (0.35) OPRM1OPRD1OPRK1CA1CA2
SCHEMBL17312415 0.87 CMA1 (0.39) ACHECRBNDDB1LMNACYP3A4
SCHEMBL17312416 0.87 CMA1 (0.39) ACHECRBNDDB1LMNACYP3A4
SCHEMBL2283972 0.84 PYGL (0.43) CRBNDDB1MAPTPYGLPYGM
SCHEMBL2281716 0.84 PYGL (0.43) CRBNDDB1MAPTPYGLPYGM
SCHEMBL17312520 0.81 BACE1 (0.34) HIF1A
SCHEMBL17312516 0.81 BACE1 (0.34) HIF1A
SCHEMBL2284752 0.80 RIPK1 (0.43) CRBNDDB1LMNACYP3A4PYGL
SCHEMBL2283134 0.80 RIPK1 (0.43) CRBNDDB1LMNACYP3A4PYGL
SCHEMBL2361799 0.80 DDB1 (0.41) OPRM1OPRK1CRBNDDB1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3508484-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-07-10 EP disclosed
US-9556152-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-01-31 US disclosed
US-20150353533-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353533-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS CNKSR1, ARAF, MAP3K3 OPRM1 1251/4885OPRD1 2325/4885OPRK1 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.